Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $98000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 75.06% year-over-year to $98000.0, compared with a TTM value of $1.1 million through Sep 2025, down 33.16%, and an annual FY2024 reading of $1.6 million, down 20.06% over the prior year.
  • Depreciation & Amortization (CF) was $98000.0 for Q3 2025 at CytomX Therapeutics, down from $310000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $643000.0 in Q3 2021 and bottomed at $98000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $487631.6, with a median of $559000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) grew 9.22% in 2021, then crashed 75.06% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $639000.0 in 2021, then decreased by 10.49% to $572000.0 in 2022, then fell by 21.5% to $449000.0 in 2023, then fell by 16.26% to $376000.0 in 2024, then plummeted by 73.94% to $98000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CTMX at $98000.0 in Q3 2025, $310000.0 in Q2 2025, and $349000.0 in Q1 2025.